{(3S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]hexahydro-2-oxo-1H-azepine-1-yl}acetic acid methyl ester | 82611-52-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: {(3S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]hexahydro-2-oxo-1H-azepine-1-yl}acetic acid methyl ester
• 英文别名: (S)-methyl 2-(3-(tert-butoxycarbonylamino)-2-oxoazepan-1-yl)acetate；methyl 3(S)-[N-(tert-butoxycarbonyl)amino]-2-oxo-1-perhydroazepineacetate；methyl 2-[(3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-oxoazepan-1-yl]acetate
• CAS: 82611-52-7
• 化学式: C₁₄H₂₄N₂O₅
• 分子量: 300.355
• InChiKey: ZESOVLWPSQEAFF-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  {(3S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]hexahydro-2-oxo-1H-azepine-1-yl}acetic acid methyl ester 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.5h， 生成 methyl 3(S)-amino-2-oxo-1-perhydroazepineacetate hydrochloride
  参考文献：
  名称：

  Synthesis and dopamine receptor modulating activity of lactam conformationally constrained analogs of Pro-Leu-Gly-NH2

  摘要：

  A series of analogues of the potent analogue of Pro-Leu-Gly-NH2 (PLG), 2-oxo-3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-1-pyrrolidineacetamide (2) were synthesized in which the (R)-gamma-lactam residue of 2 was replaced with a (R)-beta-lactam, (R)-aminosuccinimide, (R)-cycloseryl, (R)-delta-lactam, (R)-epsilon-lactam, or (S)-epsilon-lactam residue to give analogues 3-8, respectively. These substitutions were made so as to vary the psi2 torsion angle. The analogues were tested for their ability to enhance the binding of the dopamine receptor agonist ADTN to the dopamine receptor. Analogues 3-6 and 8 exhibited dose-response curves that were bell-shaped in nature with the maximum effect occurring at a concentration of 1 muM. Analogue 7 was inactive. Analogues 3 and 4 were found to be as effective as PLG, while analogues 5, 6, and 8 appeared to be more effective than PLG in terms of enhancing the binding of ADTN to dopamine receptors. The activity of analogues 3-6 and 8 with their psi2 angles in the vicinity of that observed in a type II beta-turn is consistent with the hypothesis that this type of turn is the bioactive conformation of PLG.

  DOI：

  10.1021/jm00054a010
• 作为产物：
  描述：

  (S)-3-氨基-2-己内酰胺 在 碳酸氢钠 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 18.5h， 生成 {(3S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]hexahydro-2-oxo-1H-azepine-1-yl}acetic acid methyl ester
  参考文献：
  名称：

  [EN] SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF
  [FR] AMIDES DE L'ACIDE ADIPIQUE SUBSTITUÉS ET LEURS UTILISATIONS

  摘要：

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中A是一个五至八元的单环或一个九至十二元的双环杂环环，如本文所进一步定义；Y是S、CH2或CH；Z是CH或N；R7和R9是氢或（C1-C6）烷基；R2是（C1-C6）烷氧基、羟基、氰基、（C1-C6）烷基、卤素或三氟甲基；r和s为0、1或2；R1和R3如本文所进一步定义。这些化合物是NPY4受体的激动剂、部分激动剂和/或调节剂，可用于治疗和预防肥胖、食物摄入和其他由NPY4受体调节的疾病和症状。

  公开号：

  WO2012125622A1

文献信息

• SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF
  申请人：Sun Chongqing

  公开号：US20130345123A1

  公开（公告）日：2013-12-26

  The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH 2 , or CH; Z is CH or N; R 7 and R 9 are hydrogen or (C 1 -C 6 )alkyl; R 2 is (C 1 -C 6 )alkoxy, OH, CN, (C 1 -C 6 )alkyl, halogen, or CF 3 ; r and s are 0, 1, or 2; and R 1 and R 3 are as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中A是进一步定义的五至八元杂环或九至十二元双环杂环；Y是S，CH2或CH；Z是CH或N；R7和R9是氢或（C1-C6）烷基；R2是（C1-C6）烷氧基，羟基，氰基，（C1-C6）烷基，卤素或CF3；r和s为0、1或2；而R1和R3的定义进一步如下。这些化合物是NPY4受体的激动剂、部分激动剂和/或调节剂，可用于治疗和预防肥胖、食物摄入和其他受NPY4受体调节的疾病和状况。
• Substituted adipic acid amides and uses thereof
  申请人：Sun Chongqing

  公开号：US09346852B2

  公开（公告）日：2016-05-24

  The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH2, or CH; Z is CH or N; R7 and R9 are hydrogen or (C1-C6)alkyl; R2 is (C1-C6)alkoxy, OH, CN, (C1-C6)alkyl, halogen, or CF3; r and s are 0, 1, or 2; and R1 and R3 are as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor.

  本发明提供了公式（I）的化合物或其药学上可接受的盐，其中A是进一步定义的五至八元的单环或九至十二元的双环杂环环，Y是S，CH2或CH; Z是CH或N; R7和R9是氢或（C1-C6）烷基; R2是（C1-C6）烷氧基，羟基，氰基，（C1-C6）烷基，卤素或CF3; r和s为0,1或2; R1和R3如进一步定义。这些化合物是NPY4受体的激动剂，部分激动剂和/或调节剂，可用于治疗和预防肥胖，食物摄入和其他受NPY4受体调节的疾病和状况。
• Design and synthesis of conformationally-constrained MMP inhibitors
  作者：Michael G. Natchus、Menyan Cheng、Christopher T. Wahl、Stanislaw Pikul、Neil G. Almstead、Rimma S. Bradley、Yetunde O. Taiwo、Glen E. Mieling、C.Michelle Dunaway、Catherine E. Snider、John M. McIver、Bobby L. Barnett、Sara J. McPhail、Melanie B. Anastasio、Biswanath De

  DOI：10.1016/s0960-894x(98)00370-9

  日期：1998.8

  A novel series of conformationally constrained matrix metalloprotease inhibitors was identified. The potencies observed for these inhibitors were highly dependent upon the substitution pattern on the caprolactam ring as well as the succinate moiety. (C) 1998 Elsevier Science Ltd. All rights reserved.
• US9346852B2
  申请人：——

  公开号：US9346852B2

  公开（公告）日：2016-05-24